Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib After Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma (BMT CTN #1302)

Trial Profile

Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib After Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma (BMT CTN #1302)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Ixazomib (Primary) ; Bortezomib; Fludarabine; Melphalan
  • Indications Graft-versus-host disease; Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Nov 2016 Planned End Date changed from 1 Aug 2022 to 1 Mar 2023.
    • 21 Nov 2016 Planned primary completion date changed from 1 Aug 2020 to 1 Mar 2021.
    • 21 Nov 2016 Status changed from active, no longer recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top